Treatment of Patients with ALK-positive Non-small Cell Lung Cancer and Brain Metastases
Background and objective Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is an important subtype of lung cancer. The standard modality of ALK-positive NSCLC with brain metastases remains uncertain. Methods We collected data on clinical characteristics and treatment of pa...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2016-08-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2016.08.06 |
| _version_ | 1818180568799510528 |
|---|---|
| author | Jialin LV Quan ZHANG Na QIN Xinjie YANG Xinyong ZHANG Yuhua WU Xi LI Hui ZHANG Jinghui WANG Shucai ZHANG |
| author_facet | Jialin LV Quan ZHANG Na QIN Xinjie YANG Xinyong ZHANG Yuhua WU Xi LI Hui ZHANG Jinghui WANG Shucai ZHANG |
| author_sort | Jialin LV |
| collection | DOAJ |
| description | Background and objective Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is an important subtype of lung cancer. The standard modality of ALK-positive NSCLC with brain metastases remains uncertain. Methods We collected data on clinical characteristics and treatment of patients with ALK-positive NSCLC and brain metastases between March 2013 and March 2016 and retrospectively analyzed patient outcomes. Results In 84 ALK-positive patients with advanced NSCLC, 22 (26.2%) had brain metastases during the initial diagnosis of lung cancer, among which 3 patients with EGFR mutation were excluded, and 19 patients were analyzed. Median intracranial progression-free survival (PFS) was 12.0 months. PFS for patients who received first-line local brain therapy (P=0.021) and crizotinib therapy (P=0.030) was superior to PFS for patients without such therapies. PFS for patients who received first-line crizotinib combined with local brain therapy was 27.0 months and only 4.2 months for those who received crizotinib alone. Conclusion First-line crizotinib therapy combined with local brain treatment can improve intracranial PFS for ALK-positive NSCLC with brain metastases. This finding should be confirmed further through multicenter, prospective clinical trials with large sample size. |
| first_indexed | 2024-12-11T21:21:51Z |
| format | Article |
| id | doaj.art-b4bdaa9b389546d4acf11dd2a6bc51a5 |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-12-11T21:21:51Z |
| publishDate | 2016-08-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-b4bdaa9b389546d4acf11dd2a6bc51a52022-12-22T00:50:26ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872016-08-0119851952410.3779/j.issn.1009-3419.2016.08.06Treatment of Patients with ALK-positive Non-small Cell Lung Cancer
and Brain MetastasesJialin LV0Quan ZHANG1Na QIN2Xinjie YANG3Xinyong ZHANG4Yuhua WU5Xi LI6Hui ZHANG7Jinghui WANG8Shucai ZHANG9Department of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, ChinaBackground and objective Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is an important subtype of lung cancer. The standard modality of ALK-positive NSCLC with brain metastases remains uncertain. Methods We collected data on clinical characteristics and treatment of patients with ALK-positive NSCLC and brain metastases between March 2013 and March 2016 and retrospectively analyzed patient outcomes. Results In 84 ALK-positive patients with advanced NSCLC, 22 (26.2%) had brain metastases during the initial diagnosis of lung cancer, among which 3 patients with EGFR mutation were excluded, and 19 patients were analyzed. Median intracranial progression-free survival (PFS) was 12.0 months. PFS for patients who received first-line local brain therapy (P=0.021) and crizotinib therapy (P=0.030) was superior to PFS for patients without such therapies. PFS for patients who received first-line crizotinib combined with local brain therapy was 27.0 months and only 4.2 months for those who received crizotinib alone. Conclusion First-line crizotinib therapy combined with local brain treatment can improve intracranial PFS for ALK-positive NSCLC with brain metastases. This finding should be confirmed further through multicenter, prospective clinical trials with large sample size.http://dx.doi.org/10.3779/j.issn.1009-3419.2016.08.06Lung neoplasmsALKBrain metastases |
| spellingShingle | Jialin LV Quan ZHANG Na QIN Xinjie YANG Xinyong ZHANG Yuhua WU Xi LI Hui ZHANG Jinghui WANG Shucai ZHANG Treatment of Patients with ALK-positive Non-small Cell Lung Cancer and Brain Metastases Chinese Journal of Lung Cancer Lung neoplasms ALK Brain metastases |
| title | Treatment of Patients with ALK-positive Non-small Cell Lung Cancer
and Brain Metastases |
| title_full | Treatment of Patients with ALK-positive Non-small Cell Lung Cancer
and Brain Metastases |
| title_fullStr | Treatment of Patients with ALK-positive Non-small Cell Lung Cancer
and Brain Metastases |
| title_full_unstemmed | Treatment of Patients with ALK-positive Non-small Cell Lung Cancer
and Brain Metastases |
| title_short | Treatment of Patients with ALK-positive Non-small Cell Lung Cancer
and Brain Metastases |
| title_sort | treatment of patients with alk positive non small cell lung cancer
and brain metastases |
| topic | Lung neoplasms ALK Brain metastases |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2016.08.06 |
| work_keys_str_mv | AT jialinlv treatmentofpatientswithalkpositivenonsmallcelllungcancerandbrainmetastases AT quanzhang treatmentofpatientswithalkpositivenonsmallcelllungcancerandbrainmetastases AT naqin treatmentofpatientswithalkpositivenonsmallcelllungcancerandbrainmetastases AT xinjieyang treatmentofpatientswithalkpositivenonsmallcelllungcancerandbrainmetastases AT xinyongzhang treatmentofpatientswithalkpositivenonsmallcelllungcancerandbrainmetastases AT yuhuawu treatmentofpatientswithalkpositivenonsmallcelllungcancerandbrainmetastases AT xili treatmentofpatientswithalkpositivenonsmallcelllungcancerandbrainmetastases AT huizhang treatmentofpatientswithalkpositivenonsmallcelllungcancerandbrainmetastases AT jinghuiwang treatmentofpatientswithalkpositivenonsmallcelllungcancerandbrainmetastases AT shucaizhang treatmentofpatientswithalkpositivenonsmallcelllungcancerandbrainmetastases |